Kalydeco (kuh-LYE-deh-koh), a new treatment for cystic fibrosis (CF)
You'll hear about Kalydeco (kuh-LYE-deh-koh), a new treatment for cystic fibrosis (CF).
Kalydeco (ivacaftor) is the first drug that treats the underlying genetic mutation that causes CF...not just its symptoms.
Unfortunately, it'll only help patients with a rare mutation that affects about 4% of CF patients...about 1200 people in the U.S.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote